Annals of oncology : official journal of the European Society for Medical Oncology
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial.
C Wang, W Wang, H Liu, Q Chen, C Chen, L Liu, P Zhang, G Zhao, F Yang, G Han, B Yu, Y Yang, H Chen, J Jiang, L Tan
Published: 202510.1016/j.annonc.2025.11.017
Abstract
BACKGROUND: Perioperative immunotherapy, particularly anti-programmed cell death protein 1 therapy, combined with neoadjuvant chemotherapy has emerged as one of the standard-of-care options for resectable non-small-cell lung cancer (NSCLC). We report…
Preview only. Read the full abstract at the source